EUVIMEDEUVIMED entdecken
Crossref

Dasatinib, a Novel Abl-Src Kinase Inhibitor, in the Management of Patients with Philadelphia Chromosome–Positive Leukemias

Tariq I. Mughal

Clinical Leukemia · 2006

DOI: 10.3816/clk.2006.n.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Leukemia, 2006. Verfasst von Tariq I. Mughal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Mughal, T. I. (2006). Dasatinib, a Novel Abl-Src Kinase Inhibitor, in the Management of Patients with Philadelphia Chromosome–Positive Leukemias. Clinical Leukemia. https://doi.org/10.3816/clk.2006.n.003

Vancouver

Mughal TI. Dasatinib, a Novel Abl-Src Kinase Inhibitor, in the Management of Patients with Philadelphia Chromosome–Positive Leukemias. Clinical Leukemia. 2006. doi:10.3816/clk.2006.n.003

BibTeX
@article{Mughal2006,
  author = {Mughal, Tariq I.},
  title = {Dasatinib, a Novel Abl-Src Kinase Inhibitor, in the Management of Patients with Philadelphia Chromosome–Positive Leukemias},
  journal = {Clinical Leukemia},
  year = {2006},
  doi = {10.3816/clk.2006.n.003}
}
Kostenlos starten →